Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis

Rheumatology (United Kingdom)

Volumn 54, Issue 5, 2014, Pages 784-791

  KobayashiN , Norimoto ^a   Takezaki, Shunichiro ^b   Kobayashi, Ichiro ^b   Iwata, Naomi ^c   Mori, Masaaki ^d   Nagai, Kazushige ^e   Nakano, Naoko ^f   Miyoshi, Mari ^g   Kinjo, Noriko ^h   Murata, Takuji ⁱ   Masunaga, Kenji ^j   Umebayashi, Hiroaki ^k   Imagawa, Tomoyuki ^l   Agematsu, Kazunaga ^m   Sato, Shinji ⁿ   Kuwana, Masataka ^o   Yamada, Masafumi ^b   Takei, Shuji ^p   Yokota, Shumpei ^d   Koike, Kenichi ^a   Ariga, Tadashi ^b   more..

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

^d YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KOBE CHILDREN S HOSPITAL   (Japan)

^h UNIVERSITY OF THE RYUKYUS   (Japan)

ⁱ OSAKA MEDICAL COLLEGE   (Japan)

^j KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k MIYAGI CHILDREN S HOSPITAL   (Japan)

^l KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^m SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p KAGOSHIMA UNIVERSITY   (Japan)

more..

Author keywords

Anti melanoma differentiationassociated gene 5; Ferritin; Interleukin 18; Interstitial lung disease; Juvenile dermatomyositis; KL 6

Indexed keywords

ANTIBODY; CREATINE KINASE; CYCLOSPORIN A; FERRITIN; INTERLEUKIN 18; KREBS VON DEN LUNGEN 6 PROTEIN; MDA 5 PROTEIN; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; METHYLPREDNISOLONE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE; RARE DISEASE;

EID: 84929663587     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu385     Document Type: Article

References (45)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
2. Mendez EP, Lipton R, Ramsey-Goldman R et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
3. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nationwide study. Br J Rheumatol 1995;34:732-6.
4. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr 1964;64:101-31.
5. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
6. Ravelli A, Trail L, Ferrari C et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010;62:63-72.
7. Mukae H, Ishimoto H, Sakamoto N et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classical dermatomyositis. Chest 2009;136:1341-7.
8. Kobayashi S, Higuchi K, Tamaki H et al. Characteristics of juvenile dermatomyositis in Japan. Acta Paediatr Jpn 1997;39:257-62.
9. Sanner H, Aaløkken TM, Gran JT et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011;70:86-91.
10. Yokota S, Takei S, Miyoshi M et al. The Ministry of Health, Labour and Welfare of Japan Study Group Report on Severe Pediatric Rheumatic Disease. Tokyo: Ministry of Health, Labour and Welfare 2010.
11. Kobayashi I, Ono S, Kawamura N et al. A serum level of KL-6 is a marker for interstitial lung disease associated with juvenile dermatomyositis. J Pediatr 2001;138:274-6.
12. Sato S, Hirakata M, Kuwana M et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52:1571-6.
13. Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis:association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193-200.
14. Kobayashi I, Okura Y, Yamada M et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011;158:675-7.
15. Kumanovics G, Magyarlaki T, Komocsi A, Szekeres G, Czirjak L. Simultaneous presence of neutrophil alveolitis and Ki-67 positivity of alveolar macrophages in dermato-/ polymyositis and systemic sclerosis. Rheumatol Int 2003;23:6-10.
16. Tucci M, Quatraro C, Dammacco F, Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21-31.
17. Gono T, Kawaguchi Y, Sugiura T et al. Interleukin-18 is a key mediator of dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology 2010;49:1878-81.
18. Kaser A, Kaser S, Kaneider NC et al. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 2004;103:648-55.
19. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007;157:637-44.
20. Kobayashi I, Yamada M, Kawamura N et al. Plateletspecific hemophagocytosis in a patient with juvenile dermatomyositis. Acta Paediatr 2000;89:617-9.
21. Kobayashi I, Yamada M, Takahashi Y et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporine A. Rheumatology 2003;43:371-4.
22. Sakurai N, Nagai K, Tsutsumi H, Ichimiya S. Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement. J Rheumatol 2011;38:963-4.
23. Nagai Y, Mizuno T, Yoshizawa C, Ishikawa O. Fatal interstitial pneumonia in juvenile dermatomyositis. Eur J Dermatol 2010;20:208-10.
24. Ishikawa J, Shikama Y, Takahashi E, Akagi K. Rapidly progressive interstitial pneumonia with juvenile dermatomyositis [in Japanese]. J Jpn Pediatr Soc 2011;115:793-9.
25. Nonaka Y, Imanaka H, Nerome Y et al. A case of anti-Jo-1 antibody-positive juvenile dermatomyositis complicated by interstitial lung disease: successful treatment with cyclosporine A [in Japanese]. J Jpn Pediatr Soc 2008;112:719-23.
26. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr 1987;26:561-6.
27. McCann LJ, Juggins AD, Maillard SM et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 years. Rheumatology 2006;45:1255-60.
28. Huber AM, Mamyrova G, Lachenbruch PA et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2014;66:732-40.
29. Kang EH, Nakashima R, Mimori T et al. Myositis autoantibodies in Korean patients with inflammatory myositis:anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010;11:223.
30. Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000;59:372-6.
31. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/ MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013;23:496-502.
32. Nakashima R, Imura Y, Kobayashi S et al. RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 2010;49:433-40.
33. Hall JC, Casciola-Rosen L, Samedy L-A et al. Antimelanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 2013;65:1307-15.
34. Shimizu M, Yokoyama T, Yamada K et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritisassociated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 2010;49:1645-53.
35. Gono T, Miyake K, Kawaguchi Y et al. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology 2012;51:1336-8.
36. Gono T, Kawaguchi Y, Hara M et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010;49:1354-60.
37. Gono T, Kawaguchi Y, Ozeki E et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 2011;21:223-7.
38. Englund P, Wahlström J, Fathi M et al. Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007;56:372-83.
39. Kourakata H, Takada T, Suzuki E et al. Flow cytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/ dermatomyositis with interstitial pneumonia. Respirology 1999;4:223-8.
40. Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 2002;46:1430-8.
41. Satoh H, Kurishima K, Ishikawa H et al. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006;260:429-34.
42. Kohno N, Kyoizumi S, Awaya Y et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
43. Yokoyama A, Kohno N, Hamada H et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1680-4.
44. Gono T, Sato S, Kawaguchi Y et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 2012;51:1563-70.
45. Kameda H, Nagasawa H, Ogawa H et al. Combination therapy with corticosteroids, cyclosporine A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-26.